LY4152199 - IV
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Trial Timeline
Jun 1, 2026 → Mar 1, 2029
NCT ID
NCT07101328About LY4152199 - IV
LY4152199 - IV is a phase 1 stage product being developed by Eli Lilly for Lymphoma, Non-Hodgkin. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07101328. Target conditions include Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Non-Hodgkin were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07101328 | Phase 1 | Recruiting |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin